Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial With a Factorial Design Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse, From the Prostate Cancer Consortium in Europe (PEACE)

NCT06625970 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06625970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06625970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial With a Factorial Design Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse, From the Prostate Cancer Consortium in Europe (PEACE)
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Recruiting
Start date
April 10, 2025
Completion date
October 31, 2045
Enrollment
700 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

high risk prostate carcinoma, prostate cancer